Evidence map›Paper›PMID 38279217›Full record

ReviewInternational journal of molecular sciences2024

Metabolic Flexibility of the Heart: The Role of Fatty Acid Metabolism in Health, Heart Failure, and Cardiometabolic Diseases.

Virginia Actis Dato, Stephan Lange, Yoshitake Cho

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
26.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. EV-Encapsulated Mitochondrial miRNAs: Enhancing Cardiomyocyte Bioenergetics.International journal of molecular sciences · 2026
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Virginia Actis DatoDivision of Cardiovascular Medicine, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Stephan LangeDivision of Cardiovascular Medicine, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-9361-6602
Yoshitake ChoDivision of Cardiovascular Medicine, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-7161-3248
University of California San Diego · USSteno Diabetes Centers · DK

Funding

The role of obscurin and Obsl1 as key determinants for diastolic functionR01HL152251 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHO, YOSHITAKE, LANGE, STEPHAN · 2021 to 2024
$2.3M
PERM in Cardiac FunctionR01HL151239 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHO, YOSHITAKE, ROSS, ROBERT SCOTT · 2020 to 2023
$1.6M
NHLBI NIH HHS R01 HL151239NHLBI NIH HHS R01 HL152251
6 · The paper itself

Abstract

This comprehensive review explores the critical role of fatty acid (FA) metabolism in cardiac diseases, particularly heart failure (HF), and the implications for therapeutic strategies. The heart's reliance on ATP, primarily sourced from mitochondrial oxidative metabolism, underscores the significance of metabolic flexibility, with fatty acid oxidation (FAO) being a dominant source. In HF, metabolic shifts occur with an altered FA uptake and FAO, impacting mitochondrial function and contributing to disease progression. Conditions like obesity and diabetes also lead to metabolic disturbances, resulting in cardiomyopathy marked by an over-reliance on FAO, mitochondrial dysfunction, and lipotoxicity. Therapeutic approaches targeting FA metabolism in cardiac diseases have evolved, focusing on inhibiting or stimulating FAO to optimize cardiac energetics. Strategies include using CPT1A inhibitors, using PPARα agonists, and enhancing mitochondrial biogenesis and function. However, the effectiveness varies, reflecting the complexity of metabolic remodeling in HF. Hence, treatment strategies should be individualized, considering that cardiac energy metabolism is intricate and tightly regulated. The therapeutic aim is to optimize overall metabolic function, recognizing the pivotal role of FAs and the need for further research to develop effective therapies, with promising new approaches targeting mitochondrial oxidative metabolism and FAO that improve cardiac function.

Indexed as

Heart FailureMyocardiumEnergy MetabolismFatty AcidsHumansMitochondriaFatty Acidscardiometabolic diseasesfatty acid metabolismheart failuremetabolic flexibilitymitochondrial oxidative metabolism

Identifiers

PMID38279217
PMCPMC10816475
OpenAlexW4391030932

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.